Table 2 Upcoming trials assessing tyrosine kinase inhibitors in the treatment of ewing sarcoma and other tumors
From: Tyrosine kinase inhibitors in Ewing’s sarcoma: a systematic review
ClinicalTrials.gov or ISRCTN Registry Identifier | Intervention | Indication | Type of study | Number of participants | Study start date | Study completion date |
|---|---|---|---|---|---|---|
NCT06156410 | Cab + Ifosfamide | Relapsed/refractory Ewing sarcoma and osteosarcoma. | Phase I clinical trial | 30 | 2023-10-24 | 2028-11 |
NCT05182164 | Pembrolizumab + Cab | Advanced sarcomas (undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma) | Phase II clinical trial | 119 | 2022-04-25 | 2025-10-31 |
NCT05135975 | Cab | Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors who have achieved and maintained (for at least 4 weeks) a “best response” to their most recent line of therapy (high-risk pediatric solid tumors) | Phase II clinical trial | 86 | 2022-07-20 | 2029-12 |
NCT02243605 | Cab | Relapsed osteosarcoma or Ewing sarcoma after a period of improvement | Phase II clinical trial | 90 | 2014-12-19 | 2025-07-11 |
NCT02867592 | Cab | Children and young adults with recurrent/relapsed or newly diagnosed Ewing sarcoma, rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, and Wilms tumor | Phase II clinical trial | 109 | 2017-05-18 | 2025-06-25 |
NCT05395741 | Reg | Refractory Ewing’s sarcoma and osteosarcoma in children, adolescents and young adults | Phase I/II clinical trial | 30 | 2022-04-28 | 2025-12-31 |
NCT02389244 | Reg | Metastatic bone sarcomas: conventional high-grade osteosarcoma, Ewing sarcoma of bone, intermediate or high-grade chondrosarcomas and chordomas and either bone or soft tissue metastatic CIC-rearranged sarcomas | Phase II clinical trial | 163 | 2014-09 | 2025-06 |
NCT05830084 | Reg + induction chemotherapy (VDC/IE) | Newly diagnosed/ multimetastatic ewing sarcoma | Phase I clinical trial | 24 | 2023-06-16 | 2026-06 |
NCT04055220 | Reg or placebo | Patients with bone sarcoma after a first line therapy | Phase II clinical trial | 168 | 2020-03-03 | 2026-10-01 |
NCT06820957 | Vin + irino + Reg + vin + dox + CP + Ifos + Etop or VDC/IE | Newly diagnosed Ewing sarcoma or other metastatic round cell sarcomas | Phase II/III clinical trial | 437 | 2025-04-15 | 2032-07-15 |
ISRCTN17938906 | Groupe A: Induction chemotherapy and Reg Groupe B1: Radiotherapy without surgery or after surgery that cannot remove all the cancer Groupe B2: Radiotherapy after surgery where there is some cancer cells left Groupe C: Maintenance chemotherapy | Newly diagnosed Ewing’s sarcoma | Phase III clinical trial | 900 | 2024-01-22 | 2029-11-30 |
NCT04803318 | Tram + Ever + Lenv | Recurrent/ Refractory advanced solid tumors | Phase II clinical trial | 100 | 2021-01-01 | 2037-01-01 |